NLS Pharma acquires a portfolio of strategic patents
Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
NLS Pharma announces the acquisition of four patents including one linked to an innovative compound that NLS Pharma seeks to develop for the treatment of ADHD.
Attention-Deficit/Hyperactivity Disorder (ADHD) is considered by OECD as one of the most frequently monitored developmental syndromes worldwide. In the US, 11% of children 4-17 years of age (6.4 million) have been diagnosed with ADHD as of 2011 1 , and regarded by Time magazine as the icon disability of the digital age. ADHD is still far from being well-addressed.
Currently, first line treatments for ADHD mainly rely on the use of psychostimulants such as methylphenidates and amphetamines, along with the non-amphetamine-like stimulant modafinil. Certain adverse events have often been observed when using these types of products, impacting patients’ everyday life, suggesting that better options for all patients are needed.
The patent acquisition, from a leading French healthcare institution, allows NLS Pharma’s work towards a potential novel therapy in ADHD to reach a key milestone. The IP portfolio acquired in this transaction includes mazindol, a non-amphetaminic psychostimulant. NLS Pharma already participated in a Pre-Investigational New Drug ("Pre-IND") meeting concerning mazindol with the US Food and Drug Administration ("FDA").
Alex Zwyer, CEO of NLS Pharma, commented: “The IND is expected to be opened in the first quarter of 2016 and all traffic lights are now green for the next phase of development. Already published clinical open-label data 2 suggest that mazindol might be an effective, well-tolerated, and long-acting agent for the treatment of ADHD in children. This is promising evidence which has us optimistic about the future developments of this potential new treatment. We are looking forward to our next step: the upcoming launch of mazindol’s Phase IIB clinical trial and are excited to be involved in bringing new types of treatments to ADHD patients.”
Supported by a worldwide network of opinion leaders and academic institutions, relying on a team of experienced industry development experts and well-recognized pharmaceutical leaders, NLS Pharma has been created to fulfill medical needs of patients with neurobehavioral and neurocognitive disorders, where there is unmet medical need.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
EPO for the Brain - Engineered Moss produces human hormone without doping activity
ProtAffin AG granted patent in EU for CellJammer discovery technology - Novel technology enables development of a new class of biopharmaceuticals
CSIC researchers find the role of a protein in the regulation of synapse formation - The work raises the need for a balance between the Pinkman protein and the sHSPs proteins during the development of the nervous system for its correct formation
Affymetrix Selected to Genotype More Than 9,000 Framingham Heart Study Samples - SHARE Project to Help Identify Genetic Variants Associated With Heart, Lung, Blood and Sleep Disorders
New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
Northern_Norway_Pharmaceutical_Trust
Cell culture: The opportunities and the challenges - The promise of cell culture is accelerating demand, and emphasising the challenges, of this process
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
St_John_Ambulance_in_England_and_Wales
Harold_Ridley_(ophthalmologist)
Henry_Suter
